Early Targeting of Chronic Inflammation That Precedes and Causes Synaptic Loss

On this episode of Pharma's Almanac TV, our Scientific Editor in Chief, David Alvaro, talks to INmune Bio's President and CEO Raymond J. Tesi about the company's unique and revolutionary treatment of chronic inflammation that causes Alzheimer's.

Raymond J. Tesi, M.D.

Dr. Tesi has been INmune Bio’s President, Chief Executive Officer and acting Chief Medical Officer since the formation of the Company in September 2015. From November 2011 to May 2015, Dr. Tesi was CEO, President and Acting Chief Medical Officer of FPRT Bio Inc., a development-stage biotech company formed to develop XPro1595 for the treatment of neurodegenerative disease and other inflammatory diseases. From November 2010 to October 2011, Dr. Tesi was Chief Medical Officer of Adienne SRL, an emerging biotech company in Bergamo, Italy focused on products to treat patients with hematologic malignancy. From June 2007 to September 2010, Dr. Tesi was CEO and President of Coronado Biosciences, a company he founded. Dr. Tesi received his MD degree from Washington University School of Medicine in 1982. Dr. Tesi has been a licensed physician since 1982 and Fellow of the American College of Surgery since 1991.